- Home
- TBLA vs PCRX Comparison
TBLA vs PCRX Comparison
Compare TBLA & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBLA
- PCRX
- Stock Information
- Founded
- TBLA 2007
- PCRX 2006
- Country
- TBLA United States
- PCRX United States
- Employees
- TBLA N/A
- PCRX N/A
- Industry
- TBLA Computer Software: Programming Data Processing
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- TBLA Technology
- PCRX Health Care
- Exchange
- TBLA Nasdaq
- PCRX Nasdaq
- Market Cap
- TBLA 1.2B
- PCRX 1.2B
- IPO Year
- TBLA N/A
- PCRX 2011
- Fundamental
- Price
- TBLA $3.54
- PCRX $21.85
- Analyst Decision
- TBLA Strong Buy
- PCRX Buy
- Analyst Count
- TBLA 4
- PCRX 8
- Target Price
- TBLA $4.50
- PCRX $28.38
- AVG Volume (30 Days)
- TBLA 1.3M
- PCRX 506.9K
- Earning Date
- TBLA 08-06-2025
- PCRX 07-29-2025
- Dividend Yield
- TBLA N/A
- PCRX N/A
- EPS Growth
- TBLA N/A
- PCRX N/A
- EPS
- TBLA 0.04
- PCRX N/A
- Revenue
- TBLA $1,779,705,000.00
- PCRX $702,772,000.00
- Revenue This Year
- TBLA $7.69
- PCRX $7.92
- Revenue Next Year
- TBLA $6.15
- PCRX $11.02
- P/E Ratio
- TBLA $88.84
- PCRX N/A
- Revenue Growth
- TBLA 16.63
- PCRX 3.08
- 52 Week Low
- TBLA $2.50
- PCRX $11.16
- 52 Week High
- TBLA $4.30
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- TBLA 47.95
- PCRX 33.91
- Support Level
- TBLA $3.59
- PCRX $22.24
- Resistance Level
- TBLA $3.66
- PCRX $23.58
- Average True Range (ATR)
- TBLA 0.09
- PCRX 0.77
- MACD
- TBLA -0.02
- PCRX -0.05
- Stochastic Oscillator
- TBLA 8.89
- PCRX 5.16
About TBLA Taboola.com Ltd.
Taboola.com Ltd is a technology company that powers recommendations across the Open Web with an artificial intelligence-based, algorithmic engine. It partners with websites, devices, and mobile apps, collectively referred to as digital properties, to recommend editorial content and advertisements on the Open Web. Geographically it serves Israel, the United Kingdom, Germany, France, Rest of the world whilst it generates the majority of its revenue from the United States.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.